Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
-
BUSINESS 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
-
BUSINESS FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
-
REGULATORY G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
-
BUSINESS Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
-
REGULATORY LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
-
BUSINESS Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
-
BUSINESS Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
-
REGULATORY LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
-
BUSINESS Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
-
REGULATORY Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
-
BUSINESS Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
-
BUSINESS Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
-
REGULATORY Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
-
ACADEMIA Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
-
REGULATORY Japan Approves Mefeego as First Abortion Pill
May 1, 2023
-
REGULATORY Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
-
BUSINESS 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
-
ACADEMIA More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
-
BUSINESS Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…